Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

Molecular Oncology

Volumn 1, Issue 4, 2008, Pages 406-412

  Clark, Gary M ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

Epidermal growth factor receptor; Erlotinib; Histology; Non small lung cancer; Predictive; Prognostic; Smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PATIENT SELECTION; PHYSICIAN; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING;

BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SMOKING;

EID: 40849101574     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2007.12.001     Document Type: Article

References (12)

1. Birnbaum A., and Ready N. Gefitinib therapy for non-small cell lung cancer. Curr. Treat. Options Oncol. 6 (2005) 75-81
2. Buyse M., Molenberghs G., Burzykowski T., Renard D., and Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1 (2000) 49-67
3. Clark G.M., Zborowski D.M., Santabárbara P., Ding K., Whitehead M., Seymour L., and Shepherd F.A. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Clin. Lung Cancer 7 (2006) 389-394
4. Clark G.M., Zborowski D.M., Culbertson J.L., Whitehead M., Savoie M., Seymour L., and Shepherd F.A. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J. Thorac. Oncol. 1 (2006) 837-846
5. Fleming T.R. Objective response rate as a surrogate end point: a commentary. J. Clin. Oncol. 23 (2005) 4845-4846
6. Goodin S. Erlotinib: optimizing therapy with predictors of response?. Clin. Cancer Res. 12 (2006) 2961-2963
7. Hsieh R.-K., Lim K.-H., Kuo H.-T., Tzen C.-Y., and Huang M.-J. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small lung cancer. Chest 128 (2005) 317-321 10.1378/chest.128.1.317
8. Matsuo K., Ito H., Yatabe Y., Hiraki A., Hirose K., Wakai K., Kosaka T., Suzuki T., Tajima K., and Mitsudomi T. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci. 98 (2007) 96-101 10.1111/j.1349-7006.2006.00347.x
9. Shah N.T., Kris M.G., Pao W., Tyson L.B., Pizzo B.M., Heinemann M.-H., Ben-Porat L., Sachs D.L., Heelan R.T., and Miller V.A. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J. Clin. Oncol. 23 (2005) 165-174 10.1200/jco.2005.04.057
10. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. Med. 353 (2005) 123-132
11. Thatcher N., Chang A., Parikh P., Pereira J.R., Ciuleanu T., von Pawel J., Thongprasert S., Tan E.H., Pemberton K., Archer V., and Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
12. Tsao A.S., Tang X.M., Sabloff B., Xiao L., Shigematsu H., Roth J., Spitz M., Hong W.K., Gazdar A., and Wistuba I. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J. Thorac. Oncol. 1 (2006) 231-239